- Home
- MRCC vs PBYI Comparison
MRCC vs PBYI Comparison
Compare MRCC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | PBYI |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.2M | 263.4M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRCC | PBYI |
|---|---|---|
| Price | $6.34 | $5.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.00 | $7.00 |
| AVG Volume (30 Days) | 102.5K | ★ 402.3K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 15.02% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | $43,742,000.00 | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.87 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $2.58 |
| 52 Week High | $8.85 | $6.12 |
Technical Indicators
Market Signals| Indicator | MRCC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 60.04 |
| Support Level | $6.65 | $4.84 |
| Resistance Level | $6.80 | $5.92 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 10.01 | 75.93 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.